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Summary
Primary hyperparathyroidism (PHPT) is a common endocrinopa-
thy, mostly caused by a monoclonal parathyroid adenoma. This
review primarily summarizes current knowledge concerning
molecular pathogenesis of familial forms of primary hyper-
parathyroidism and sporadic (non familial) parathyroid tumors.
The hereditary syndromes have been recognized as exhibiting
Mendelian inheritance patterns and include multiple endocrine
neoplasia types 1 (MEN 1) and 2A (MEN 2A), hereditary hyper-
parathyroidism-jaw tumor (HPT-JT) syndrome, familial isolated
hyperparathyroidism (FIHP), familial hypocalciuric hypercal-
cemia (FHH) and severe neonatal hyperparathyroidism (NSHPT).
Inactivating mutations of MEN1 tumor suppressor gene are re-
sponsible for MEN 1 in >90% of cases. MEN1 gene has also an
established role in the pathogenesis of sporadic parathyroid
adenomas. Allelic loss (LOH) of chromosome 11q13 occurs in
about 30-40% and somatic mutation of MEN1 gene occur in
about 12-20% of sporadic parathyroid adenomas. A mouse mod-
el of MEN1 deficiency causes a phenotype that includes the
same range of major endocrine tumors as in MEN 1 patients,
and exhibits multistage tumor progression with metastatic po-
tential. Hormonal disturbances, such as abnormal PTH and in-
sulin levels, were also observed in these mice. Mutations in a
newly identified tumor suppressor gene, HRPT2, have been re-
cently associated with the development of HPT-JT. HRPT2 muta-
tions are also frequent in sporadic parathyroid carcinomas and
central to their pathogenesis. MEN1 and HRPT2 genes muta-
tions have also been found in a subset of FIHP families. FHH
and NSHPT represent the mildest and severest variants of PH-
PT, respectively. Both cause hypercalcemia from birth and atypi-
cal PHPT that always uniquely persists after subtotal parathy-
roidectomy. Future identification of additional oncogenes and
tumor suppressor genes will clarify the molecular basis of ab-
normalities of parathyroid proliferation and regulatory function
and other specific features unique to the parathyroid tumorigen-
esis. 
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bromin, HRPT2, MEN1, parathyroid carcinoma, cyclin D1.
Introduction
Over the past ten years, our knowledge of the molecular basis
of parathyroid neoplasia has increased substantially. Many of
the well established general themes in tumor biology appear to
be applicable to parathyroid tumorigenesis, in spite of the typi-
cally nonmalignant status of these tumors. Patients with primary
hyperparathyroidism (PHPT) have both an increased parathy-
roid proliferation and a resetting of the control of PTH secretion
(set-point abnormality) (1, 2). A full molecular description of
parathyroid tumor biology will need to explain these phenomena
and other special aspects such as the role of irradiation in pre-
disposing to parathyroid tumors, the rarity of parathyroid cancer
as compared with the abundance of benign parathyroid lesion,
and the possible role of the post menopause and/or estrogen
status. 
It is now clear that neoplasia is a genetic disease, in which the
DNA damage occurs somatically and is typically not inherited
or present in the germ cells. In general, multiple mutations (ac-
cumulating within the same cell and its progeny) are required
for the emergence and progression of the clonal status. Fur-
thermore, the monoclonality of tumors implies that the needed
accumulation of mutations occurs only rarely in a large popula-
tion of cells in a tissue.
Some genes may contribute to tumor development of only one
or a few cell types, whereas other genes may be involved in
many different types of tumors. Moreover, for most tumor cell
types it appears that a single gene is not always involved and
that different combinations of mutated genes may result in sim-
ilar cellular and clinical alteration (3, 4). 
The recognition that parathyroid adenomas are monoclonal tu-
mors generated the expectation that these general principles
would indeed apply to parathyroid tumorigenesis (4). Clonal
DNA damage of two groups of normal cellular genes (pro-
tooncogenes and tumor suppressor genes) contributes to the
development of neoplasia (5). 
Protooncogenes are often involved in the physiological control
of cellular growth, differentiation and proliferation. Conversion
of a protooncogene to an “oncogene” is caused by a deregula-
tion of the expression of its protein product or by formation of
an abnormal product. Proto-oncogene can be activated by a
variety of mechanisms, including chromosome translocation or
inversion, point mutation, proviral insertion, or gene amplifica-
tion. 
The products of tumor suppressor genes normally restrain pro-
liferation and their gene inactivation contributes to neoplasia.
Inactivation of tumor suppressor genes can occur by point mu-
tation or deletion, and may be inherited or occurs somatically.
The causes of this oncogenic “hits” are not well understood.
Some genetic changes tend to occur more commonly in mitoti-
cally active cells, and carcinogens may act either by direct mu-
tagenesis of DNA or through an increase of the mitotic rate,
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which favors the occurrence of an oncogenic chromosome
aberrancy.
Monoclonality of parathyroid adenomas
Early studies of the clonal status of parathyroid tumors assessed
X-chromosome inactivation patterns by measuring isoforms of
glucose-6-phopshate dehydrogenase in parathyroid adenomas
of women heterozygous for the polymorphism (6, 7). These stud-
ies indicated that parathyroid adenomas were polyclonal as op-
posed to monoclonal growths. The issue of the clonal status of
parathyroid tumors was reevaluated several years later, again by
X- chromosome inactivation method, using a DNA polymor-
phism-based method that avoids many of the pitfalls of the previ-
ously protein polymorphism approach. It was demonstrated that
most, if not all, parathyroid adenomas are monoclonal tumors (8-
10). This finding is consistent with the general experience that
surgical removal of such tumors is curative of the disease.
Parathyroid carcinomas, as would be expected, are also mono-
clonal. Monoclonality is a reflection of the selective advantage
gained by a parathyroid cell when a sufficient number of critical
changes in protooncogenes and/or tumor suppressor genes oc-
cur within it. Progeny of such a cell grows and accumulates addi-
tional genetic changes (this is clonal evolution), ultimately form-
ing a clinically apparent mass of cells. 
It is well known that various forms of parathyroid hyperplasia,
presumably caused by a stimulus of parathyroid cell prolifera-
tion affecting all parathyroid glands, may evolve into a mono-
clonal tumor. Indeed, monoclonality has been documented in
the majority of parathyroid tumors from patients with sporadic
PHPT and secondary (or tertiary) hyperparathyroidism of ure-
mia (10). Monoclonality also characterizes the enlarged
parathyroids of patients with multiple endocrine neoplasia type
1 (MEN 1) (11-13), but it is not known whether such outgrowth
derives from a previous stage of true polyclonal hyperplasia
that might be driven by the inherited haploinsufficiency for the
MEN1 gene.
Familial parathyroid diseases
Genetic studies on inherited tumor susceptibility disorders
have increased our knowledge of tumorigenesis. PHPT is
found in several disorders with an autosomal dominance inher-
itance, such as multiple endocrine neoplasia type 1 (MEN 1)
and 2A (MEN2A), hereditary hyperparathyroidism-jaw tumor
(HPT-JT) syndrome, familial isolated hyperparathyroidism
(FIHP), familial hypocalciuric hypercalcemia (FHH) and neona-
tal severe hyperparathyroidism (NSHPT). The genetic charac-
teristics of familial parathyroid diseases are shown in Table I. 
Multiple endocrine neoplasia type 1
Genetic mapping studies in families with MEN 1 syndrome
showed that the gene responsible is on chromosome 11q13
(14). By analogy with familial retinoblastoma, which involves in-
heritance of mutations in the Rb gene, it was suggested that
the MEN1 gene was a tumor suppressor gene. Inactivation of
both alleles is required to completely deplete the gene’s anti-
neoplastic product. A common inactivation mechanism is a so-
matic deletion of a substantial proportion of chromosomal DNA
that includes the relevant gene. This is revealed by a loss of
heterozygosity (LOH) of DNA markers in tumor DNA relative to
normal DNA of the same individual (Fig. 1). The evidence that
the MEN1 was a tumor suppressor gene was provided by the
demonstration of somatic genetic abnormalities in MEN1 tu-
mors which inactivate one allele of a gene at 11q13 and so re-
veal the inherited MEN1 mutation on the other allele (Fig. 2).
LOH of polymorphic marker DNAs from this region has been
found in the majority of MEN 1-associated tumors including
those of parathyroids (15, 16). Mutations of the MEN1 gene
have been detected in >90% of MEN1 families. The mutations
are scattered through the nine translated exons of the MEN1
gene, and approximately half the members of each family have
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Table I - Genetic characteristics of familial hyperparathyroid diseases
Disease Gene Chromosomal location Inheritance
MEN 1 MEN1 11q13 Autosomal dominant
MEN 2A RET 10q21 Autosomal dominant
HPT-JT HRPT2 1q24-32 Autosomal dominant
FIHP MEN1, HRPT2,CASR, NI* 11q13, 1q24-32, 3q21-24, ? Autosomal dominant
FHH CASR, NI 3q21-24, 19q13, 19p13.3 Autosomal dominant
NSHPT CASR 3q21-24 Autosomal recessive
* Not identified.
Figure 1 - Microsatellite length polymorphisms around MEN1 locus ana-
lyzed using polymorphic DNA markers on chromosome 11q13 in MEN
1 family. Arrows denote peaks with reduced fluorescence intensity in tu-
mor compared to blood DNA; these findings indicate loss of heterozy-
gosity.
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a mutation unique to that family, making presymptomatic ge-
netic testing laborious (17). 
Allelic loss of chromosome 11 markers occurs in about one-
third of the large number of sporadic parathyroid adenomas
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Figure 2 - Schematic representation illustrating the inactivation of MEN1 gene in MEN 1 syndrome (panel A) and in sporadic primary hyperparathy-
roidism (panel B) according to Knudson’s hypothesis. Panel A. A mutant copy of MEN1 gene is inherited in MEN 1 and present in all parathyroid
cells. A second somatic deletion/mutation of the remaining normal allele leads to a clonal progenitor cell that lacks functional gene product with the
development of the tumor. Panel B. Mutation of one allele of the same gene may occur somatically in specific parathyroid cell(s). A second somatic
deletion/mutation of the remaining normal allele leads to a clonal progenitor cell that lacks functional gene product with the development of the tumor.
Table II - Menin interacting proteins.
Interacting proteins Functions of interacting protein
Nuclear
JunD Trascriptional regulation
Smad1, Smad3, Smad5, Runx2 Trascriptional regulation
NFkB Trascriptional regulation
Pem Trascriptional regulation
RPA2 DNA processing and repair
FANCD2 DNA processing and repair
Double-stranded DNA DNA processing and repair
Cytoplasmic
GFAP and vimentin Cytoskeletal organization
NMMHC IIA Cytoskeletal organization
Rat nm23-beta GTPase activity
Nuclear and cytoplasmic
Hsp70 and CHIP Protein degradation
MEN1 gene
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(18-24), and usually involves loss of the region to which the
MEN1 gene has been mapped. By analogy to the Rb tumor
suppressor gene mode, in which the sporadic counterpart of
the Rb tumor results from somatic genetic events leading to
loss or inactivation of both normal Rb gene alleles (Fig. 2),
some sporadic parathyroid adenomas may evolve from a clon-
al precursor with biallelic inactivation of the MEN1 gene. Bial-
lelic-acquired inactivating MEN1 mutations have been de-
scribed in 12-20% of sporadic parathyroid adenomas (18-24). 
The MEN1 gene encodes a 610 amino acid protein, named
menin, with no strong homology to known proteins. Menin is
expressed ubiquitously and found predominantly in the nucleus
(25). Sequence analyses do not reveal motifs of known func-
tion other than two nuclear localization sequences. Menin has
been found to partner in vitro with a variety of proteins that
comprise transcription factors, DNA processing factors, DNA
repair proteins, and cytoskeletal proteins (Table II). The differ-
ent functions of menin interactors suggest roles for menin in
multiple biological pathways. Inactivation of menin switches its
JUND partner from downstream action of growth suppression
to growth promotion (25-27).
To examine the role of menin in tumor development, two
mouse models of MEN1 deficiency have been generated (28,
29). Heterozygous MEN1 mutant mice develop the same range
of major endocrine tumors as seen in MEN 1 patients, affecting
parathyroid, pancreatic islets, pituitary and adrenal glands, and
exhibiting multistage tumor progression with metastatic poten-
tial (28). Hormonal disturbances (29), such as abnormal PTH
and insulin levels, have also been observed in these mice.
These tumors were associated with LOH of the wild type MEN1
allele, suggesting that menin is involved in suppressing the de-
velopment of these endocrine tumors. All of these features are
reminiscent of MEN 1 symptoms in humans and establish het-
erozygous MEN 1 mutant mice as a suitable model for this dis-
ease.
Multiple endocrine neoplasia type 2 A
Germline gain-of-function mutations in the RET protooncogene
cause MEN 2A (30). The RET protein is a receptor tyrosine ki-
nase that normally transduces growth and differentiation sig-
nals in developing tissues including those derived from the
neural crest. This makes the RET gene, which encodes a tyro-
sine kinase receptor, a candidate gene involved in nonfamilial
hyperparathyroidism. There are both differences and much
overlap in the specific RET gene mutations underlying MEN 2A
and familial medullary thyroid cancer (FMTC); in contrast MEN
2B is caused by entirely distinct RET mutations (31). The rea-
son for which parathyroid disease fails to develop in FMTC pa-
tients who can bear identical RET mutations as found in MEN
2A remains unclear. Unlike the several different inactivating
mutations of MEN1, which are typical of a tumor suppressor
mechanism, RET mutations in MEN 2A are limited in number,
reflecting the need for specific gain-of-function changes to acti-
vate this oncogene (32). RET mutation at codon 634 seems to
be highly associated with the expression of PHPT in MEN 2A.
MEN2 type RET mutations have been implicated in the patho-
genesis of some sporadic medullary thyroid carcinomas and
pheocromocytomas (33). Up to date no RET mutations have
been found in sporadic parathyroid adenomas (34, 35). RET is
expressed in both MEN 2A parathyroid adenomas and in spo-
radic adenomas (31). This suggests that parathyroid disease is
an integral part of the MEN 2A, but that RET do not play a role
in the pathogenesis of sporadic parathyroid adenomas.
Hereditary hyperparathyroidism-jaw tumor syndrome
Mutations in a newly identified tumor suppressor gene,
HRPT2, have been recently associated with HPT-JT syndrome
and with sporadic parathyroid carcinoma (36-39). The HPT-JT
syndrome is a rare autosomal disorder consisting of parathy-
roid tumors, ossifying fibromas of the mandible and maxilla,
and occasionally renal hamartomas and cystic kidney disease.
The HRPT2 gene maps on chromosome 1q24-32 and it func-
tions as a tumor suppressor gene. For its inactivation two “hits”
must occur: first an inactivating mutation on one allele, then a
second hit, either a mutation or deletion, in the remaining nor-
mal allele (identified in the tumor as LOH of polymorphic mark-
ers at HRPT2 locus). HRPT2 encodes a protein of 531 amino
acid called parafibromin and is present in other tissues in addi-
tion to the parathyroids, such as kidney, heart, adrenal and
skeletal muscle (36). Subcellular fractionation and laser confo-
cal microscopy of normal human parathyroid gland demon-
strated expression of parafibromin in both cytoplasmic and nu-
clear compartments. Parafibromin is a member of the human
Paf1 complex which has been proposed to regulate transcrip-
tion and chromatin modification (40).
Currently there is convincing evidence that HRPT2 mutations
are associated with parathyroid carcinomas. HRPT2 is the tar-
get for germline mutation in the majority of families with the
rare HPT-JT, in which parathyroid carcinoma occurs at higher
frequency than in sporadic PHPT (15% vs <1%). Indeed,
parathyroid carcinoma occurs frequently in HPT-JT cases than
in sporadic PHPT. Moreover, recent studies identified HRPT2
somatic or germline mutations in sporadic parathyroid cancer
(37-39) (see below).
Familial isolated hyperparathyroidism
FIHP is a clinically defined entity, based on the absence of ex-
pression of the extra-parathyroid manifestations that character-
ize other familial HPT syndromes. FIHP is genetically hetero-
geneous, and can be caused by variant expressions of
germline mutations in MEN1, HRPT2, CASR, and probably
other genes (41-55).
One of the puzzling aspects of FIHP is the absence of some of
the manifestations of the syndromic forms despite the fact that
the same gene is affected. Several possible mechanisms might
account for this finding: i) incomplete penetrance of some of
the manifestations, as the gnathic and renal features in HPT-
JT (41, 43); ii) difference in the spectrum of mutations: it has
been suggested that missense/in-frame deletion mutations
may lead to incomplete MEN 1 phenotype, whereas truncating
or nonsense mutations are more frequently observed in the
full-blown syndrome (15). However, recent results from our (39,
55) and other groups (37, 41-55) have ruled out this possibility;
iii) different mutations of the same gene may result in various
degree of structure change and, accordingly, the capability of
the mutated protein of interacting with other proteins may be
variously affected. Indeed, either naturally occurring or engi-
neered MEN1 gene mutations have been shown to affect dif-
ferently binding of menin with JunD (25); iv) influences from en-
vironmental factors and the presence of modifier genes that
may contribute to phenotypic variations, as reported in familial
adenomatous polyposis (56).
Familial hypocalciuric hypercalcemia and neonatal severe
hyperparathyroidism
FHH is an autosomal dominant syndrome characterized by life-
long moderate hypercalcemia, inappropriate serum PTH levels,
126 Clinical Cases in Mineral and Bone Metabolism 2006; 3(2): 123-131
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and relative hypocalciuria. Parathyroid gland are normal in
most patients with FHH (57, 58). In some families, however,
PTH is moderately elevated. The biochemical abnormality of
FHH has been attributed to the increased renal retention of cal-
cium that is not quite enough to overcome the decreased
parathyroid sensitivity to calcium, so that PTH concentration is
inappropriately normal. In rare cases PTH is moderately elevat-
ed, suggesting that decreased parathyroid sensitivity to calci-
um is accompanied by a moderate generalized parathyroid hy-
perplasia (59). This observation suggests that the CASR may
be involved in the control of parathyroid proliferation (see be-
low).
FHH mostly maps to CASR gene locus on chromosome 3q21-
24, but genetic heterogeneity has been substantiated with two
kindreds that show linkage to either 19p13.3 (FHH 19p) or
19q13 (FHH 19p) also known as Oklahoma variant (60-62). Het-
erozygous and homozygous loss-of-function mutation of CASR
gene are responsible for FHH and NSHP, respectively. CASR
is ubiquitous but it is most heavily expressed in the parathyroid
cells and the thick ascending loop of the kidney (59). It has
three main structural domains: a large extracellular amino-ter-
minal domain, a seven transmembrane spanning domain,
which characterizes the superfamily of G-protein coupled re-
ceptors, and an intracytoplasmic carboxy terminal tail. CASR
interacts with extracellular calcium ions, transducing it into an
intracellular signal, its protein category products coupling to a
cytoplasmic guanyl nucleotide-binding protein. No correlation
between the CASR mutation spectrum and the clinical pheno-
type has been apparent in FHH families. CASR inactivating
mutations may interfere with normal function of the wild-type
receptor through the following mechanisms: a) reduced affinity
of the receptor for its agonists including calcium; b) inability of
the receptor to reach the cell surface; c) failure of the receptor
to couple with its appropriate signal transduction pathways;
and d) interference of the mutated receptor with the function of
the wild type receptor, known as a “dominant negative” effect
or production of a truncated, inactive receptor.
One large family has been described with a phenotype differ-
ent from FHH and FIHP. These patients had hypercalcemia,
hypercalciuria, and serum PTH levels in the upper part of the
normal range. Some family members had parathyroid adeno-
ma or hyperplasia and, unlike FHH, had postoperative reversal
of hypercalcemia. Genetic studies identified an atypical inacti-
vating mutation in the intracellular part of the CASR (63).
NSHPT is often diagnosed within a week of birth and may car-
ry a very high mortality rate unless recognized and treated
promptly. The severity of the hypercalcemia, bone disease and
high PTH levels is mostly explained by the absence of CASR
in the homozygous and compound heterozygous forms of
NSHPT. The dramatic increase of parathyroid gland volume
suggests a negative trophic effect of the normal CASR on cell
growth and proliferation.
Gene knockout model (64) provided the definitive proof for the
central role for the normal CASR in calcium metabolism and of
inactivating mutations in causing the FHH and NSHPT pheno-
types. Heterozygous mice had about a 50% reduction in the ex-
pression of the CASR protein both in the parathyroid gland and
the kidney compared with the wild type mice. They were similar
to wild type mice with normal skeletal films and parathyroid
gland histology. They had mild hypercalcemia with normal PTH
levels, hypocalciuria and mildly elevated serum magnesium
compared with the wild-type mice. In the mutant mice there was
a mild elevation of the set point for calcium-regulated PTH re-
lease, similar to what has been reported in FHH families. Ho-
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Figure 3 - Loss of heterozygosity (LOH) and mutation of the HRPT2 gene in a patient with sporadic parathyroid carcinoma. Tumor DNA shows a bial-
lelic inactivation of the gene due to LOH (left panel, arrow), associated with a somatic mutation (195insT) in exon 2 (right panel) (Modified from refer-
ence 39).
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mozygous mice had a complete absence of CASR protein in
the parathyroid and kidney. The phenotypic and biochemical
profiles of these mice was comparable to that of NSHPT. 
Genetic abnormalities in sporadic parathyroid adenomas
To date cyclin D1/parathyroid adenomatosis gene 1 (PRAD1)
together with the MEN1 is the only gene with an established
role in the development of sporadic (nonfamilial) parathyroid
adenomas. 
The cyclin D1/parathyroid adenomatosis gene 1 oncogene
The cyclin D1/PRAD1 gene was identified as a parathyroid
oncogene on chromosome 11q13, clonally activated in a sub-
set of parathyroid adenomas by tumor-specific DNA rearrange-
ment with the parathyroid hormone (PTH) gene locus (65-67).
The rearrangement separated the 5’ regulatory region and the
noncoding exon 1 of the PTH gene from its coding exons, with
different, non-PTH DNA, placed adjacent to each PTH gene
section with a pericentromeric inversion of chromosome 11,
bringing the PRAD1 (normally on 11q) under the control of the
PTH gene 5’ flanking region (on 11p) (Fig. 4). (The tumor cells
has one intact PTH gene that accounted for expression of PTH
by the tumor). This rearrangement causes transcriptional acti-
vation and overexpression of the PRAD1 gene (Fig. 5) (68,
69). Consequent to its discovery as a parathyroid oncogene,
cyclin D1 has become established as a major and broad con-
tributor to other neoplasia such as breast cancer, multiple
mieloma, B-cell lymphomas and others (70, 71).
The cyclin D1 gene encodes a 295 amino acid protein homolo-
gous to members of cyclin class of proteins (70). Cyclins play
an important role in the regulation of cell cycle progression,
and human cyclins have been grouped in different types ac-
cording to sequence similarity (70). The C, D and E type cy-
clins appear to be G1 cyclins which regulate the progression
throught G1 phase and the G1-S transition, determining whether
initiation of a new cell cycle occurs. During G1, cyclin D1 com-
plexes with and activates its kinase partner, cyclin-dependent
kinase (CDK) CDK4 or CDK6, depending on tissue type. The
activated kinase is involved in the phosphorylation and inacti-
vation of retinoblastoma protein (pRb), determining progres-
sion toward S-phase. It is thought, therefore, that overexpres-
sion or deregulated expression of cyclin D1 could quite con-
ceivably accelerate the cell’s progress through G1 into S
phase, bypassing normal regulatory controls in committing to
divide, and also be well tolerated by the cell during the remain-
der of the cycle. Such a mechanism would provide an appeal-
ing explanation for the benign nature of parathyroid adenomas,
because it could yield excessive cellular proliferation without
necessarily conferring the phenotype of invasiveness or metas-
tasis to the tumor cell. 
Functional studies have shown that the effects of cyclin D1 on
proliferation are mediated throught its ability to phosphorylate
and thereby inactivate pRb. It appears that the cyclin D1-
CDK4/6-p16-Rb pathway has become aberrant in virtually
every human tumor. In recent years, our understanding of the
mechanisms by which cyclins regulate proliferation and differ-
entiation has evolved and accumulating evidence suggests
that, in addition to its original description as a CDK-dependent
regulator of the cell cycle, cyclin D1 also conveys cell cycle or
CDK-independent functions. Cyclin D1 regulates activity of
transcription factors, coactivators and corepressors that govern
histone acetylation and chromatin remodeling proteins. The re-
cent findings that cyclin D1 regulates cellular metabolism, fat
cell differentiation and cellular migration have refocused atten-
tion on novel functions of cyclin D1 and their possible role in tu-
morigenesis (70).
In different parathyroid adenomas, the 11q13 chromosome
breakpoint can be positioned within 1-2 kb of cyclin D1, or as
much 300 kb upstream and further. Because these gene break
points could vary widely they can be missed with traditional ap-
proaches (i.e. Southern blotting) and we may not have there-
fore a precise percentage of the rearrangements in parathyroid
neoplasia. The best estimate to date of the frequency of the in-
volvement of cyclin D1 expression come from assessment of
expression at the protein level. Immunohistochemical studies
have shown a cyclin D1 overexpression in 20-40% of parathy-
roid adenomas (68, 69).
To define the role of cyclin D1 in parathyroid neoplasia, and to
investigate the relationship between proliferative and hormonal
regulatory abnormalities in this disease, a transgenic mouse
model with parathyroid-targeted overexpression of cyclin D1
128 Clinical Cases in Mineral and Bone Metabolism 2006; 3(2): 123-131
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Figure 4 - Schematic diagram illustrating the pericentromeric chromoso-
mal inversion that occurred in parathyroid adenomas. The PTH gene’s
5’-regulatory region is rearranged upstream of cyclin D1/PRAD1, and
the cyclin D1 gene is overexpressed by the PTH promoter.
Figure 5 - Schematic diagram of the molecular structure of the PTH/
PRAD1 DNA rearrangement and its functional consequences. The sign
X represents the chromosomal breakpoint between the PTH gene regu-
latory region, plus PTH 5’ region.
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has been developed (72). These mice carry a transgene in
which the cyclin D1 gene is placed adiacent to a 5.2 kb frag-
ment of the PTH regulatory region, thereby mimicking the DNA
rearrangement and cyclin D1 overexpression observed in hu-
man tumors. The phenotype of these mice was very similar to
that of patients with PHPT. The parathyroid glands were hyper-
cellular with increased proliferative rates (72) and, in some cas-
es, they develop parathyroid adenomas. PTH-cyclin D1 mice
developed not only abnormal parathyroid cell proliferation but
also biochemical hyperparathyroidism, with the characteristic
bone abnormalities. The transgenic mice show decreased
bone volume and increased bone turnover, with increased
numbers of osteoclasts and reduced bone formation. This high
turnover phenotype has marked similarities with the human
bone under the influence of PTH excess.
Notably, these mice had an increase in the PTH-calcium set
point, similar to that observed in the human disease. Thus, cy-
clin D1 may not only control cellular proliferation but also con-
tribute to abnormal hormonal secretion. In a recent article (73),
the same authors, using this animal model, analyzed the tem-
poral sequences of proliferative and set point abnormalities
that occur in parathyroid tumorigenesis. They demonstrate that
abnormal parathyroid proliferation regularly precedes dysregu-
lation of the calcium-PTH axis, supporting the concept that dis-
turbed parathyroid proliferation is the crucial primary initiator
leading to the development of the biochemical phenotype of
PHPT. In addition, they observed that decreased expression of
the CASR in the parathyroid glands occurs several months be-
fore development of biochemical PHPT, suggesting that de-
creased CASR may not be sufficient to cause PTH dysregula-
tion in this animal model of PHPT. In contrast, mice that exhibit
a similarly decreased level of CASR but, as a result of a
germline heterozygous knockout of the CASR gene, demon-
strate a clear rightward shift in the set point curve with hyper-
calcemia and inappropriate PTH level. It is possible, that the
stage of development at which alteration is imposed (embryon-
ic/germline vs. postnatal/acquired) may lead to different pheno-
type. These data suggest that the typical reduction in CASR
expression in parathyroid adenoma may not be the only deter-
minant of the altered set point of the tumor cells. It has been al-
so hypothesized that somatic mutations that inactivate the
CASR gene play an important role in parathyroid tumorigene-
sis. However, CASR mutations are not observed in sporadic
parathyroid adenomas (74, 75). It has been suggested that
other factors such as functional activity of the CASR or oscilla-
tions of intracellular Ca2+ may play a role in the CASR-mediat-
ed signaling. Furthermore, the primary cyclin D1 abnormalities,
may have a more direct role in regulating the expression of
CASR.
Genetic abnormalities in sporadic parathyroid carcinoma
Parathyroid carcinoma is usually associated with more severe
clinical manifestations of PHPT than parathyroid adenomas.
The incidence of parathyroid cancer does not favor women but
is matched between the sexes, and the age of onset is approx-
imately earlier than in benign disease (mid-40yr instead of the
mid-50yr). The principal histological features of parathyroid car-
cinoma include mitoses, tick fibrous bands, and capsular and
blood vessel invasion (76). However, the distinction between
benign and malignant parathyroid tumors cannot be definitively
established in the absence of local invasion or metastases
(77). Nonetheless, these features are not always clearly pre-
sent and certainly identify a late stage of the disease with a
poor prognosis and low cure rate. 
In 1994 Cryns et al. (78) reported that inactivation of the Rb1
gene might be involved in the pathogenesis of parathyroid car-
cinoma and that this finding might be a useful tool for the diag-
nosis of parathyroid malignancy; since then, contradictory re-
sults have been obtained by other investigators (79). Our
group, recently, further investigated the role of the Rb1 gene in
the differential diagnosis between benign and malignant
parathyroid tumors by evaluating LOH at this locus and pRb
immunohistochemistry (79). We show that Rb1 gene alter-
ations are not specific for parathyroid cancer. Retention of Rb
heterozygosity excludes such diagnosis, which is suggested by
the combined finding of LOH and lack of pRb expression. How-
ever, the same authors who previously reported that inactiva-
tion of Rb1 is a key factor in the pathogenesis of many or most
parathyroid carcinomas, showed no microdeletion, insertions
or point mutations in the coding regions and promoter of the
Rb1 gene in a small series of parathyroid carcinomas (80). 
Recent studies (37-39) have found an involvement of HRPT2
gene in the pathogenesis of sporadic parathyroid cancer. Shat-
tuck et al. (38) found HRPT2 mutations in 10 of 15 patients
with apparently sporadic parathyroid carcinoma; three of the
patients had HRPT2 germline mutations. Howell et al. (37) de-
tected HRPT2 somatic mutation in four of four parathyroid car-
cinoma. Our group (39) identified HRPT2 mutations in six of
seven parathyroid carcinomas. Thus HRPT2 mutation is patho-
genic for most sporadic parathyroid carcinomas. Combining all
the results the prevalence of HRPT2 mutations in sporadic
parathyroid carcinomas is 77% (Table III). It is conceivable that
inactivating mutation of non coding or regulatory regions could
be also implicated in the pathogenesis of sporadic parathyroid
cancer. Thus, HRPT2 mutation is central to the pathogenesis
of most, and perhaps virtually all sporadic parathyroid carcino-
ma.
Preliminary reports of immunostaining for parafibromin (81),
have shown that the loss of immunoreactivity to parafibromin
has a high sensitivity and specificity for diagnosing parathyroid
carcinoma.
The high rate of HRPT2 mutation in carcinomas also suggests
the potential diagnostic utility of HRPT2 mutation status. How-
ever, this diagnostic potential hinges on the frequency of muta-
tion in benign parathyroid adenomas. The prevalence of PHPT
is one to five per 1000 in the general population and approxi-
mately 2% in postmenopausal women. It can be attributed to a
benign, single adenoma in 80% of cases and occasionally <1%
to parathyroid carcinoma. Thus, even a low detection rate of
HRPT2 mutation in parathyroid adenomas could adversely im-
pact the diagnostic specificity and positive predictive value of
HRPT2 mutation status to differentiate between adenomas and
carcinomas. Carpten et al. (36), detected mutations in two of
47 parathyroid adenomas that were selected for their cystic
features, a specific characteristic of tumors of HPT-JT. A study
by our group found a single mutation among 35 sporadic ade-
nomas selected to exclude cases containing LOH at 11q13. In
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Table III - Prevalence of HRPT2 mutations in sporadic parathyroid
carcinomas.
Authors N. samples Mutations
Howell et al. () 4 4/4
Shattuck et al. () 15 10/15a
Cetani et al. () 7 6/7b
Totals 26 20/26
a Three of ten patients had germline mutations.
b Two of six patients had germline mutations.
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contrast two studies of unselected parathyroid adenomas (37,
84) did not detected HRPT2 mutations. Combining the data
from the latter two groups (85 tumors) the prevalence of
HRPT2 mutation was zero. If all the data of these studies (se-
lected and unselected adenomas, n= 167) were combined a
prevalence of 1.8% was found. However, as suggested by
Krebs et al. (82), a better estimate may be 0.8% (1/120) de-
rived from the study of Krebs, Howell (37) and our group (39).
These observations indicates that HRPT2 mutations are not an
important participant in the pathogenesis of typical sporadic
adenomas.
Up to date tests for HRPT2 or parafibromin are not commer-
cially available, but these tools could be a way in the future to
distinguish between parathyroid carcinoma and adenoma at
the time of initial surgery. Will HRPT2 be a useful screening
test? As suggested by Rubin et al. (83), the screening test
could be performed in the following conditions: a) patients with
severe benign PHPT, i.e. patients with clinical manifestations
similar to parathyroid carcinoma; b) patients with atypical ade-
nomas, i.e tumors containing features such as fibrous bands,
mitotic figures, or microscopic invasion, but without distant
metastases or gross invasion of surrounding structures and
thus lacking the diagnostically definitive features of carcinoma;
c) patients with parafibromatosis, in which multiple recurrent
nodules of hyperfunctioning parathyroid tissue are found in the
neck and mediastinum; d) patients in whom one has a clinical
suspicious for parathyroid cancer before or after initial surgery.
If the mutation is found, the likelihood of malignancy is certainly
increased and a more aggressive surgery and family screening
would be indicated. We agree with Rubin et al. (83), that
HRPT2 status would be a valuable piece of information to add
to conventional clinical parameters of parathyroid carcinoma.
This test will be very helpful if it directs us to an aggressive sur-
gical approach when it is needed, because this is the only cure
for this disease. 
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